Molecular Diagnosis of the Tissue of Origin in Cancer of Unknown Primary Site: Useful in Patient Management
- 29 August 2013
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 14 (4) , 634-642
Abstract
Cancer of unknown primary site (CUP) is a clinicopathologic syndrome consisting of many types of cancer and accounting for approximately 3 % of all patients with advanced cancers. This syndrome has frustrated patients and physicians for decades, because a primary site or tissue of origin has not been possible to identify clinically, despite the presence of metastatic tumor. Favorable subsets (approximately 20 % of all CUP) with a presumptive occult primary site have been recognized for several decades based on clinical and standard pathologic features; site-specific therapy in these patients improves their survival compared with the majority of other (approximately 80 %) CUP patients. These other patients, most with adenocarcinomas, have been difficult to treat because the tissue of origin was unknown. Broad-spectrum empiric chemotherapy became the standard approach for these patients in the past 30 years. More recently, new diagnostic technology (evolving immunohistochemistry and emergent gene-expression profiling) has enabled us to establish accurately a tissue of origin in most (90 %+) CUP patients. Gene-expression profiling assays complement standard pathology and for the majority of biopsy specimens accurately identify the primary site or tissue of origin; clinical studies have supported the value of site-directed therapy. When the tissue of origin is in doubt after standard pathologic examination, a gene expression assay is frequently diagnostic, and the outcome of many CUP patients is improved with site-specific therapy. The era of empiric therapy has ended in favor of site-specific therapy, based on the precise diagnosis of the tumor type present in each patient.Keywords
This publication has 30 references indexed in Scilit:
- Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primaryMolecular Cancer, 2013
- A Primary Approach to Cancers of Unknown PrimaryJNCI: Journal of the National Cancer Institute, 2013
- Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard PathologyJNCI: Journal of the National Cancer Institute, 2013
- Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancerDiagnostic Pathology, 2012
- Papillary Renal Carcinoma Presenting as a Cancer of Unknown Primary (CUP) and Diagnosed through Gene Expression ProfilingCase Reports in Oncology, 2012
- Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown PrimaryClinical Cancer Research, 2011
- Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin PredictionThe Oncologist, 2010
- Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown PrimaryJournal of Clinical Oncology, 2008
- Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primaryBritish Journal of Cancer, 2008
- MicroRNAs accurately identify cancer tissue originNature Biotechnology, 2008